Explore this issueMay 2013
Also by this Author
SNOWMASS, COLO.—Audience participation was enthusiastic during a session titled, “Panel on Therapy,” here at the ACR Winter Rheumatology Symposium, held January 26–February 1, 2013. Four experts convened onstage to respond to questions about current therapies for rheumatic disease. The panel included the moderator, Michael E. Weinblatt, MD, John R. Riedman Professor of Medicine at Brigham and Women’s Hospital in Boston, Mass., as well as Christopher T. Ritchlin, MD, MPH, professor of medicine at the University of Rochester Medical Center in Rochester, N.Y.; Joel M. Kremer, MD, director of research at the Center for Rheumatology, Albany, N.Y.; and Eric L. Matteson, MD, chair of the division of rheumatology at the Mayo Clinic in Rochester, Minn. Topics of discussion ranged from biologics to combination therapy, and the foursome frequently cited research findings to support their recommendations, reinforcing the importance of understanding the evidence and not extrapolating beyond it.
To start the evening session, Dr. Weinblatt posed a question to the panel regarding appropriate timing for starting a biologic after a patient receives the zoster vaccine. Drs. Matteson and Weinblatt agreed that four weeks was a reasonable timeframe. “Data from the literature suggests that is an adequate period to ensure that there’s not going to be dissemination, but it’s not a hard rule,” Dr. Matteson stated.